Treatment

Dorothee Heemskerk; Maxine Caws; Ben Marais; Jeremy Farrar

doi:10.1007/978-3-319-19132-4_5

Treatment

Dorothee Heemskerk
, Maxine Caws
, Ben Marais
, Jeremy Farrar

Clinical Sciences

University of Oxford
The Children's Hospital at Westmead
Wellcome Trust

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Abstract

In this chapter the treatment of drug sensitive and drug resistant TB and timing of antiretroviral treatment for HIV infected patients will be reviewed. Emphasis is placed on results of recent trials of fluoroquinolones for treatment shortening of drug sensitive TB. The use of two relatively novel agents in MDR-TB treatment, bedaquiline and delamanid, will be discussed.

Original language	English
Title of host publication	SpringerBriefs in Public Health
Pages	39-49
Number of pages	11
DOIs	https://doi.org/10.1007/978-3-319-19132-4_5
Publication status	Published - 1 Jan 2015

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Antiretroviral therapy (ARV, ART)
Bedaquiline
Delamanid
Ethambutol
First-line antituberculous treatment
Fluoroquinolones
HIV associated tuberculosis
Isoniazid
Pyrazinamide
Rifampicin
Streptomycin
Treatment of drug-resistant tuberculosis

Access to Document

10.1007/978-3-319-19132-4_5

Cite this

@inbook{d679ca3a454a4a2294a59c1b10632dde,

title = "Treatment",

abstract = "In this chapter the treatment of drug sensitive and drug resistant TB and timing of antiretroviral treatment for HIV infected patients will be reviewed. Emphasis is placed on results of recent trials of fluoroquinolones for treatment shortening of drug sensitive TB. The use of two relatively novel agents in MDR-TB treatment, bedaquiline and delamanid, will be discussed.",

keywords = "Antiretroviral therapy (ARV, ART), Bedaquiline, Delamanid, Ethambutol, First-line antituberculous treatment, Fluoroquinolones, HIV associated tuberculosis, Isoniazid, Pyrazinamide, Rifampicin, Streptomycin, Treatment of drug-resistant tuberculosis",

author = "Dorothee Heemskerk and Maxine Caws and Ben Marais and Jeremy Farrar",

year = "2015",

month = jan,

day = "1",

doi = "10.1007/978-3-319-19132-4\_5",

language = "English",

pages = "39--49",

booktitle = "SpringerBriefs in Public Health",

}

TY - CHAP

T1 - Treatment

AU - Heemskerk, Dorothee

AU - Caws, Maxine

AU - Marais, Ben

AU - Farrar, Jeremy

PY - 2015/1/1

Y1 - 2015/1/1

N2 - In this chapter the treatment of drug sensitive and drug resistant TB and timing of antiretroviral treatment for HIV infected patients will be reviewed. Emphasis is placed on results of recent trials of fluoroquinolones for treatment shortening of drug sensitive TB. The use of two relatively novel agents in MDR-TB treatment, bedaquiline and delamanid, will be discussed.

AB - In this chapter the treatment of drug sensitive and drug resistant TB and timing of antiretroviral treatment for HIV infected patients will be reviewed. Emphasis is placed on results of recent trials of fluoroquinolones for treatment shortening of drug sensitive TB. The use of two relatively novel agents in MDR-TB treatment, bedaquiline and delamanid, will be discussed.

KW - Antiretroviral therapy (ARV, ART)

KW - Bedaquiline

KW - Delamanid

KW - Ethambutol

KW - First-line antituberculous treatment

KW - Fluoroquinolones

KW - HIV associated tuberculosis

KW - Isoniazid

KW - Pyrazinamide

KW - Rifampicin

KW - Streptomycin

KW - Treatment of drug-resistant tuberculosis

U2 - 10.1007/978-3-319-19132-4_5

DO - 10.1007/978-3-319-19132-4_5

M3 - Chapter

SP - 39

EP - 49

BT - SpringerBriefs in Public Health

ER -

Treatment

Abstract

UN SDGs

Keywords

Access to Document

Fingerprint

Cite this